|
|
|
| |
Thrombotargets has developed and adapted to High Throughput Screening, a new family of biological assays capable to quantify simultaneously clot formation and clot lysis (HemostaScreen), total antioxidant capacity (OxidantScreen) and low-density lipoprotein modification (AtheroScreen). With these proven proprietary new HTS Platforms ( ), Thrombotargets is creating a continuously novel and promising pipeline of drug candidates.
|
|
|
|
|
|
|
We are convinced that patients will prefer topical medications for thrombosis treatment. Our company has developed a novel and innovative approach to traditional High Throughput Screening that will change the way lead compounds are identified in the areas of Hemostasis, Atherosclerosis, Aging and Thrombosis.
New biotech drug for deep vein thrombosis symptoms. TT-105 is a monoclonal antibody that shows high potency, good selectivity and demonstrates high efficacy in ex-vivo human experiments and in several in vivo animal models.
Thrombotargets is the biotech company that develops new medicines (recombinant DNA, molecular biology and small molecule drug technologies) for superficial thrombosis and other kinds of coagulation diseases.
Know the novel hemostatic drug generation TT-103MH got through BioplatformScreen by Thrombotargets. For topical treatment of bleeding disorders.
|
|
|
|
